Maribeth Follmer
Family · Nashville, TNNPI 1053470062
Payments from drug & device makers
Across 390 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- GSK$906
- Boehringer Ingelheim$613
- AstraZeneca$583
- Astellas Pharma US Inc$482
- AbbVie$385
- plus $2K from 27 others
What the payments were for
- Food & beverage$7,485100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 119 | $2,377 |
| GSK | 46 | $906 |
| Boehringer Ingelheim | 36 | $613 |
| AstraZeneca(2 entities) | 33 | $583 |
| Astellas Pharma US Inc | 25 | $482 |
| AbbVie | 18 | $385 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $348 |
| Pfizer | 16 | $294 |
| Exact Sciences | 13 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $198 |
| Johnson & Johnson | 9 | $170 |
| Sanofi-aventis U.S. LLC | 12 | $166 |
| Amgen | 8 | $115 |
| Lilly USA, LLC | 5 | $96 |
| Biohaven Pharmaceuticals, Inc. | 5 | $87 |
| Bayer | 3 | $56 |
| Cequr Corporation | 1 | $38 |
| IBSA Pharma Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Dexcom, Inc. | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Lifescan, Inc. | 1 | $14 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$121
How this compares
$7,485 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $91,442 |
| JardianceEmpagliflozin | 35 | $48,552 |
| EliquisApixaban | 36 | $43,646 |
| MounjaroTirzepatide | 22 | $25,676 |
| JanuviaSitagliptin Phosphate | 11 | $18,322 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $18,201 |
| MyrbetriqMirabegron | 32 | $14,160 |
| LinzessLinaclotide | 12 | $13,671 |
| XareltoRivaroxaban | 16 | $13,159 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,837 |
| Atorvastatin Calcium | 266 | $2,608 |
| Omeprazole | 141 | $2,195 |
| Levothyroxine Sodium | 238 | $2,147 |
| Celecoxib | 24 | $2,072 |
| Duloxetine Hcl | 85 | $1,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,377 | $91,44272 claims |
| Boehringer IngelheimJardiance | $613 | $48,55235 claims |
| PfizerEliquis | $294 | $43,64636 claims |
| Lilly USA, LLCMounjaro | $96 | $25,67622 claims |
| MerckJanuvia | $13 | $18,32211 claims |
| GSKTrelegy Ellipta | $906 | $18,20118 claims |
| AbbVieLinzess, Synthroid | $385 | $14,93338 claims |
| Astellas Pharma US IncMyrbetriq | $482 | $14,16032 claims |
| Johnson & JohnsonXarelto | $170 | $13,15916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Nashville
- Tamera ThoenerNashville$254K
- Jennifer WilliamsNashville$213K
- Lori LankfordNashville$148K
- Melissa RikalNashville$144K
- Nicole DelliseNashville$67K
- Lesley BallanceNashville$63K
- Jeffrey WoodsNashville$38K
- Courtney HavillNashville$35K
- Collette UtleyNashville$28K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.